Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Bariatric Gastric Banding Safer Than Gastric Bypass

By HospiMedica staff writers
Posted on 12 Mar 2007
A new study has found that laparoscopic adjustable gastric banding (LAGB) results in significantly fewer complications, shorter operative times, and shorter hospital stays when compared with laparoscopic Roux-en Y gastric bypass (LRYGB).

Researchers from the Legacy Good Samaritan Obesity Institute (Portland, OR, USA) researched a prospectively maintained database and included a total of 898 severely obese patients who underwent surgical procedures between October 2000 and October 2005. More...
Of the 898 patients, 492 (55%) underwent LRYGB and 406 (45%) underwent LAGB.

After adjusting for the differences in patient risks of the two groups before surgery, the researchers found that the LAGB procedure was associated with half the rate of potentially life-threatening complications compared to LRYGB. LAGB patients also experienced about two-thirds the overall complication rate of LRYGB patients (24% versus 32%, respectively). LAGB was also associated with approximately half the surgery time and less than half the length of hospital stay when compared to LRYGB. Rates of re-operation were the same for both groups (17%) as well as rates of 90-day deaths (0.2%). Deaths were determined not to be related to either of the surgical procedures, with the exception of one death in the LRYGB group. The study was published in the January-February 2007 issue of Surgery for Obesity and Related Diseases.

"Given the lack of comparative data available from experienced institutions that frequently perform both laparoscopic adjustable gastric banding and laparoscopic Roux-en Y gastric bypass, we believe this study provides important insights for both bariatric surgeons and their patients on the safety of two of the most common surgical treatment options for obesity,” said lead author Emma J. Patterson, M.D., medical director of the Legacy Institute.

All patients undergoing LAGB received the LapBand system, made by Allergan (Irvine, CA, USA; www.lapband.com), which is the only adjustable implant device for individualized weight loss approved by the U.S. Food and Drug Administration (FDA).


Related Links:
Legacy Good Samaritan Obesity Institute
Allergan

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Silver Member
X-Ray QA Device
Accu-Gold+ Touch Pro
Mammography System (Analog)
MAM VENUS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The researchers grew pancreatic tissue (above) so it incorporated a mesh-like electronic network (red). Cells within the tissue produce insulin (green). (Photo courtesy of Penn Medicine)

‘Cyborg’ Transplants Could Replace Pancreatic Tissue Damaged by Diabetes

Type 1 diabetes destroys insulin-producing islet cells, forcing patients to rely on lifelong insulin therapy or scarce organ transplants. Although lab-grown pancreatic tissue offers a promising alternative,... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.